IDEAYA Biosciences

IDEAYA Biosciences is a South San Francisco precision oncology company working on synthetic lethality, metabolic and epigenetic tumour dependencies. Its lead programme, darovasertib (a PKC inhibitor), is in phase 3 registrational trials in metastatic uveal melanoma and, with crizotinib, as adjuvant therapy in primary uveal melanoma (the OptimUM-11 trial with Servier dosed its first patient in September 2026), plus phase 2 studies in GNAQ/11-mutant tumours. In August 2026 the company reported that the registrational OptimUM-02 trial of the darovasertib combination in metastatic uveal melanoma met its primary endpoint, with median progression-free survival of 6.9 months against 3.1 months on investigator's choice of treatment (blinded central review, hazard ratio 0.42), and that a new drug application was under way under the FDA's Real-Time Oncology Review, with completion expected in the second half of 2026. Other programmes include IDE849, a DLL3-directed topoisomerase 1 antibody-drug conjugate in phase 1/2 for small cell lung cancer, for which the company reported FDA agreement on a phase 3 design in August 2026; IDE034 (B7H3/PTK7 ADC); IDE161 (PARG inhibitor); IDE397 (MAT2A inhibitor, phase 2) and IDE892 (PRMT5) for MTAP-deleted cancers; and IDE574 (KAT6/7). IDEAYA listed on Nasdaq in May 2019, raising 57.5 million US dollars gross in its IPO.